ABOUT US

Our focus on glycogen synthase kinase-3β (the enzyme GSK-3β) has led to the development of the therapeutic candidate elraglusib (formerly known as 9-ING-41). Elraglusib has shown tremendous potential in the treatment of many different cancers when used alone or in combination with other types of cancer therapies, including chemotherapy and immune modulators such as checkpoint inhibitors. It is our belief that this versatile agent will improve clinical outcomes for patients suffering from advanced, hard-to-treat cancers.

LEADERSHIP

Daniel M. Schmitt
Daniel M. Schmitt
President & Chief Executive Officer
Andrew P. Mazar, Ph.D.
Andrew P. Mazar, Ph.D.
Chief Operating Officer
Paul Lytle
Paul Lytle
Chief Financial Officer
Susan Gallipoli
Susan Gallipoli, RN, MSN
Senior Director, Pharmacovigilance
Carrie Kellinger
Carrie Kellinger
Senior Director, Operations
Richard Kenley
Richard Kenley, Ph.D.
Vice President, Chemistry, Manufacturing, & Controls
Austin Koukol
Austin Koukol
Project Manager for Operations and Translational Science
Sarah Majka
Sarah Majka
Associate Manager, Clinical Operations
Stevens Reich
Steven D. Reich, MD
Vice President, Clinical Development
Chris Seifarth
Chris Seifarth
Vice President, Operations and Quality Assurance
Andrey Ugolkov
Andrey Ugolkov, MD, PhD 
Senior Director, Clinical Science 

BOARD OF DIRECTORS

Aaron G.L. Fletcher, Ph.D.
Chairman
Todd Thomson
Director
Dan Zabrowski, Ph.D.
Director
Daniel M. Schmitt
President & Chief Executive Officer
Roger Sawhney
Director
Amy Ronneberg
Director
Jason Keyes
Director

Scientific Advisory Board

TIMELINE

Take a look at the Actuate journey; where we’ve been, where we are, and where we are going. Click the button below to see our company’s history.

<   ACTUATE TIMELINE   >

PARTNERING

As we continue to develop novel therapies to improve outcomes for patients. We are open to new partnerships with academic and scientific organizations.

<    COLLABORATE WITH US    >